Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | afamitresgene autoleucel |
Synonyms | |
Therapy Description |
Tecelra (afamitresgene autoleucel) are autologous T-cells that are modified to express a T-cell receptor that recognizes the human melanoma antigen 4 (MAGE-A4) peptide region from 230-239, which potentially inhibits growth of MAGE-A4-expressing tumor cells (PMID: 32002290). Tecelra (afamitresgene autoleucel) is FDA-approved for use in patients with MAGE-A4-positive unresectable or metastatic synovial sarcoma who have received prior chemotherapy, and are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
afamitresgene autoleucel | Tecelra | MAGE-A4 SPEAR T cells|MAGE-A4C1032T|ADP-A2M4 cells|afami-cel | Tecelra (afamitresgene autoleucel) are autologous T-cells that are modified to express a T-cell receptor that recognizes the human melanoma antigen 4 (MAGE-A4) peptide region from 230-239, which potentially inhibits growth of MAGE-A4-expressing tumor cells (PMID: 32002290). Tecelra (afamitresgene autoleucel) is FDA-approved for use in patients with MAGE-A4-positive unresectable or metastatic synovial sarcoma who have received prior chemotherapy, and are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04044768 | Phase II | afamitresgene autoleucel | Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | Recruiting | USA | GBR | FRA | ESP | CAN | 0 |
NCT03132922 | Phase I | afamitresgene autoleucel | MAGE-A4c1032T for Multi-Tumor | Active, not recruiting | USA | CAN | 0 |
NCT04044859 | Phase I | afamitresgene autoleucel afamitresgene autoleucel + Pembrolizumab afamitresgene autoleucel + Nivolumab | ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | Recruiting | USA | ESP | CAN | BEL | 0 |